Literature DB >> 15564551

Breast cancer--loss of PTEN predicts resistance to treatment.

Pier Paolo Pandolfi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15564551     DOI： 10.1056/NEJMcibr043143

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  57 in total

Review 1.  Molecular pathways: intercellular PTEN and the potential of PTEN restoration therapy.

Authors:  Benjamin D Hopkins; Ramon E Parsons
Journal:  Clin Cancer Res       Date:  2014-11-01       Impact factor: 12.531

2.  Trastuzumab.

Authors:  Annelies H Boekhout; Jos H Beijnen; Jan H M Schellens
Journal:  Oncologist       Date:  2011-05-31

3.  Hyperactivation of phosphatidylinositol-3 kinase promotes escape from hormone dependence in estrogen receptor-positive human breast cancer.

Authors:  Todd W Miller; Bryan T Hennessy; Ana M González-Angulo; Emily M Fox; Gordon B Mills; Heidi Chen; Catherine Higham; Carlos García-Echeverría; Yu Shyr; Carlos L Arteaga
Journal:  J Clin Invest       Date:  2010-06-07       Impact factor: 14.808

4.  Impact of KRAS mutation and PTEN expression on cetuximab-treated colorectal cancer.

Authors:  Fang-Hua Li; Lin Shen; Zhuang-Hua Li; Hui-Yan Luo; Miao-Zhen Qiu; Hui-Zhong Zhang; Yu-Hong Li; Rui-Hua Xu
Journal:  World J Gastroenterol       Date:  2010-12-14       Impact factor: 5.742

5.  Resistance to Trastuzumab in Breast Cancer.

Authors:  Paula R Pohlmann; Ingrid A Mayer; Ray Mernaugh
Journal:  Clin Cancer Res       Date:  2009-12-15       Impact factor: 12.531

Review 6.  Salivary gland carcinomas.

Authors:  Tobias Ettl; Stephan Schwarz-Furlan; Martin Gosau; Torsten E Reichert
Journal:  Oral Maxillofac Surg       Date:  2012-07-29

7.  Aberrations of MET are associated with copy number gain of EGFR and loss of PTEN and predict poor outcome in patients with salivary gland cancer.

Authors:  Tobias Ach; Katharina Zeitler; Stephan Schwarz-Furlan; Katharina Baader; Abbas Agaimy; Christian Rohrmeier; Johannes Zenk; Martin Gosau; Torsten E Reichert; Gero Brockhoff; Tobias Ettl
Journal:  Virchows Arch       Date:  2012-12-15       Impact factor: 4.064

8.  Aspirin Suppresses Growth in PI3K-Mutant Breast Cancer by Activating AMPK and Inhibiting mTORC1 Signaling.

Authors:  Whitney S Henry; Tyler Laszewski; Tiffany Tsang; Francisco Beca; Andrew H Beck; Sandra S McAllister; Alex Toker
Journal:  Cancer Res       Date:  2016-12-09       Impact factor: 12.701

9.  Patterns of basal signaling heterogeneity can distinguish cellular populations with different drug sensitivities.

Authors:  Dinesh Kumar Singh; Chin-Jen Ku; Chonlarat Wichaidit; Robert J Steininger; Lani F Wu; Steven J Altschuler
Journal:  Mol Syst Biol       Date:  2010-05-11       Impact factor: 11.429

10.  Prolyl isomerase Pin1 is highly expressed in Her2-positive breast cancer and regulates erbB2 protein stability.

Authors:  Prudence B Lam; Laura N Burga; Bryan P Wu; Erin W Hofstatter; Kun Ping Lu; Gerburg M Wulf
Journal:  Mol Cancer       Date:  2008-12-15       Impact factor: 27.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.